HCW Biologics Inc. Form 8-K Summary
Reporting date: May 3, 2024. The filing reports an Item 4.02 event concerning non-reliance on previously issued financial statements for the year ended December 31, 2023.
Business Context and Reporting Period
HCW Biologics, a Delaware biotechnology company listed on Nasdaq under HCWB, disclosed that it was the victim of a criminal impersonation scheme involving a purported purchaser of secured notes.
Financial and Liquidity Matters
- A legally binding commitment to purchase $8.0 million of secured notes went into default.
- Approximately $1.3 million held in Company accounts was misdirected to a fraudulent account controlled by a third party.
- The default invalidated an assumption used in management’s assessment of the Company’s ability to continue as a going concern.
- The filing states that the required disclosure changes did not affect cash position, results of operations, or other financial information reported in the December 31, 2023 financial statements.
- The filing does not provide updated revenue, profit, cash flow, margin, debt, or liquidity balances.
Material Changes and Restatement
On May 3, 2024, the Audit Committee concluded that the December 31, 2023 financial statements should be restated and could no longer be relied upon. The Company plans to amend its 2023 Form 10-K to revise disclosures regarding risk factors, ineffective disclosure controls and internal control over financial reporting, the related material weakness, and going-concern and liquidity considerations.
The identified material weakness relates to internal controls over financing transactions and increases the risk of material misstatements in financial statements and disclosures. Grant Thornton LLP, the independent registered public accounting firm, discussed these matters with management and the Audit Committee.
Outlook, Risks, and Unusual Items
- The Board and Audit Committee are conducting an internal investigation with outside advisors into the criminal scheme and the note-purchase default.
- Management will evaluate remediation measures, which may include additional procedures and controls for financing transactions.
- The Company expects to file the amended Form 10-K as soon as practicable, but the filing does not provide a definitive filing date.
- Important uncertainties include the ultimate amount of the fraud-related loss, the Company’s ability to remediate controls, and the outcome of the going-concern analysis.
- The filing indicates that substantial doubt regarding the Company’s ability to continue as a going concern must be reassessed without relying on the flawed financing assumption.
Investor Verification Checklist
- Verify the amended Form 10-K and revised going-concern disclosures when filed.
- Review the final amount and accounting treatment of the approximately $1.3 million misdirected funds.
- Assess the status and outcome of the internal investigation and any related recovery efforts or claims.
- Review the remediation plan and any subsequent disclosures regarding the material weakness in financing controls.
- Confirm updated cash, liquidity, financing, and going-concern information in subsequent SEC filings.